Biotech sector experiences IPO market recovery led by US firms

Biotech companies are returning to public equity markets following a prolonged period of inactivity, with US-based firms capturing the majority of the momentum. European participation remains constrained, suggesting a divergence in regional capital market health and investor appetite for high-risk biotech assets.